Benadryl is not being taken off the market. The product remains widely available over the counter in the United States, and no FDA action has been finalized to remove it. However, a citizen petition filed in 2025 is actively requesting that the FDA remove oral diphenhydramine (Benadryl’s active ingredient) from all over-the-counter cough, cold, and allergy products. That petition is currently open for review, which is likely fueling the concern behind this question.
What the FDA Petition Actually Requests
The petition, filed under docket ID FDA-2025-P-6950, asks the FDA to pull oral diphenhydramine from the OTC monograph for cough, cold, and allergy products. This is a citizen petition, meaning it was submitted by an individual or organization rather than initiated by the FDA itself. The FDA is required to review and respond to such petitions, but the vast majority do not result in a product being removed from shelves.
A citizen petition is essentially a formal request. It opens a public comment period, goes through internal FDA review, and can take months or even years to resolve. The docket is classified as “nonrulemaking,” meaning it has not triggered any proposed regulation. At this point, no timeline exists for a decision, and Benadryl remains fully legal to sell and purchase.
Why Safety Concerns Keep Coming Up
The petition didn’t appear out of nowhere. Diphenhydramine belongs to a class of drugs called anticholinergics, which block a chemical messenger involved in memory, attention, and muscle control. These drugs have been under increasing scrutiny for years, particularly for their effects on older adults.
A widely cited study found that taking an anticholinergic drug for the equivalent of three years or more was associated with a 54% higher risk of dementia compared to taking the same dose for three months or less. Diphenhydramine scores a 3 on the anticholinergic cognitive burden scale developed at Indiana University School of Medicine, placing it in the highest-risk category. Beyond dementia risk, these drugs are known to cause confusion and increase fall risk in older people, which is why geriatricians have been advising against routine use in seniors for over a decade.
For younger, healthy adults using Benadryl occasionally for allergies or a bad cold, the risk profile is different. The concerns center on long-term or frequent use, and on populations that are more vulnerable to the drug’s sedating and cognitive effects.
The Phenylephrine Connection
Some of the confusion around Benadryl and FDA action may stem from a related but separate story. In September 2023, an FDA advisory committee unanimously concluded that oral phenylephrine, a nasal decongestant found in many cold and allergy products, does not work at its recommended OTC dose. The FDA subsequently proposed removing oral phenylephrine from the OTC monograph entirely.
This matters for Benadryl because one version of the product, Benadryl Allergy Plus Congestion, contains both diphenhydramine (25 mg) and phenylephrine (10 mg). If the FDA finalizes its proposal on phenylephrine, that specific combination product would need to be reformulated or pulled. But the classic Benadryl Allergy product, which contains only diphenhydramine, is unaffected by the phenylephrine ruling.
Restrictions in Other Countries
Outside the U.S., regulators have already tightened access to diphenhydramine for certain age groups. The UK’s Medicines and Healthcare products Regulatory Agency ruled that cough and cold medicines containing diphenhydramine should no longer be used in children under 6, concluding that the balance of benefits and risks has not been shown to be favorable in that age group. Children ages 6 to 12 can still access these products, but only through pharmacies where a pharmacist can provide guidance.
The U.S. has no equivalent age restriction specific to diphenhydramine, though the FDA has issued broader warnings about cough and cold products in very young children.
Newer Antihistamines as Alternatives
Part of the case against diphenhydramine rests on the fact that newer antihistamines work just as well with fewer side effects. Cetirizine (sold as Zyrtec) and loratadine (sold as Claritin) are second-generation antihistamines that were designed to relieve allergy symptoms without crossing into the brain as easily, which means less drowsiness.
Head-to-head comparisons show that cetirizine and diphenhydramine have similar onset of action and similar effectiveness at controlling allergic reactions. The key difference is sedation. In one double-blind study comparing the two drugs during allergic reactions, diphenhydramine caused noticeably more drowsiness, with 26% of patients becoming drowsy and 8.6% falling asleep, compared to 17% and 2.9% for cetirizine. Second-generation antihistamines also last longer, typically providing 24 hours of relief from a single dose compared to 4 to 6 hours for Benadryl.
For most people managing seasonal allergies or mild allergic reactions, a newer antihistamine offers the same relief without the sedation, cognitive fog, or anticholinergic burden. Diphenhydramine still has a role in acute allergic reactions and as a short-term sleep aid, but its position as a go-to allergy medication has eroded significantly as safer options have become available, all at comparable prices.
What This Means Right Now
Benadryl is still on store shelves and is not subject to any active recall or removal order. The open citizen petition is worth watching, but citizen petitions frequently result in denial or partial action rather than the sweeping removal being requested. Even if the FDA were to act, the process would involve a proposed rule, a public comment period, and a final rule, a timeline that typically stretches over years.
If you’re using Benadryl occasionally for allergies or sleep, nothing has changed in terms of its legal availability. If you’re using it regularly, especially if you’re over 65, the existing safety data is reason enough to talk with a pharmacist about switching to a second-generation antihistamine regardless of what happens with the petition.